SCOPUS 정보 검색 플랫폼

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue 2, 2001, Pages 109-114

A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer

(7) Olver, I a Davy, M a Luftner D a Park, S H a Egorin, M a Ellis, Andrew b Webster, Lorraine b

a ROYAL ADELAIDE HOSPITAL (Australia)

b PETER MACCALLUM CANCER CENTRE (Australia)

Author keywords

Altretamine; Ovarian cancer; Paclitaxel; Pharmacokinetics

Indexed keywords

ALTRETAMINE; CISPLATIN; HEXALAN; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LETHARGY; MYALGIA; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ALTRETAMINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 0034906338 PISSN: 03445704 EISSN: None Source Type: Journal
DOI: 10.1007/s002800000263 Document Type: Article

Times cited : (3)

References (28)

1
- 0030881725
- Salvage weekly paclitaxel in recurrent ovarian cancer
- (1997) Semin Oncol , vol.24 , pp. S15-S62
- Abu-Rustum, N.R.¹ Aghajanian, C.² Barakat, R.R.³ Fennelly, D.⁴ Shapiro, F.⁵ Spriggs, D.⁶

2
- 0028045095
- Paclitaxel: What schedule? What dose?
- (1994) J Clin Oncol , vol.12 , pp. 233
- Arbuck, S.G.¹

3
- 0027502156
- The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense Taxol and granulocyte colony stimulating factor
- (1993) Anticancer Drugs , vol.4 , pp. 141
- Bicher, A.¹ Kohn, E.² Sarosy, G.³ Davis, P.⁴ Adamo, D.O.⁵ Jacob, J.⁶ Christian, M.⁷ Reed, E.⁸

4
- 0032978688
- Comparison of standard and CA 125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel
- (1999) J Clin Oncol , vol.17 , pp. 501
- Bridgewater, J.A.¹ Nelstrap, A.E.² Rustin, G.J.³ Gore, M.E.⁴ McGuire, W.P.⁵ Hoskins, W.J.P.⁶

5
- 0018387530
- A program package for simulation and parameter estimation in pharmacokinetic systems
- (1979) Comput Prog Biomed , vol.9 , pp. 115
- D'Argenio, D.Z.¹ Schumitzky, A.²

6
- 0031106191
- Extended phase II study of paclitaxel as a 3 h infusion in patients with ovarian cancer previously treated with platinum
- (1997) Eur J Cancer , vol.33 , pp. 379
- Du Bois, A.¹ Luck, H.J.² Buser, K.³ Meerpohl, H.G.⁴ Sessa, C.⁵ Klaassen, U.⁶ Meden, H.⁷ Bochtler, H.⁸ Diergarten, K.⁹

7
- 0027999966
- European-Canadian randomised trial of paclitaxel in relapsed ovarian cancer: High dose versus low dose and long versus short infusion
- (1994) J Clin Oncol , vol.12 , pp. 2654
- Eisenhauer, E.A.¹ Ten Bokkel Huinink, W.W.² Swenerton, K.D.³

8
- 0030561358
- Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer
- (1996) Gynecol Oncol , vol.63 , pp. 312
- Goldberg, J.M.¹ Piver, M.S.² Hempling, R.E.³ Recio, F.O.⁴

9
- 0001192953
- A randomised comparison of paclitaxel (T) and carboplatin (J) versus a control arm of single agent carboplatin or CAP (cyclophosphamide, doxorubicin and cisplatin): 2075 Patients randomised into the Third International Collaborative Ovarian Neoplasm Study (ICON3)
- (1999) Proc Am Soc Clin Oncol , vol.18 , pp. 1375
- Harper, P.¹

10
- 0022409449
- Phase II trial of VP-16-213 in advanced ovarian carcinoma
- (1985) Gynecol Oncol , vol.22 , pp. 162
- Hillcoat, B.L.¹ Campbell, J.J.² Pepperell, R.³ Quinn, M.A.⁴ Bishop, J.F.⁵ Day, A.⁶

11
- 0029044165
- Paclitaxel pharmacokinetics and pharmacodynamics
- (1995) Semin Oncol , vol.22 , pp. 16
- Kearns, C.M.¹ Gianni, L.² Egorin, M.J.³

12
- 0028020890
- Phase II study of gemcitabine (2,2-difiourodeoxycytidine) in previously treated ovarian cancer patients
- (1994) J Natl Cancer Inst , vol.86 , pp. 1530
- Lund, B.¹ Hansen, O.P.² Theilade, K.³ Hansen, M.⁴ Neijt, J.P.⁵

13
- 0026086870
- Secondline platinum therapy with ovarian cancer previously treated with cisplatin
- (1991) J Clin Oncol , vol.9 , pp. 389
- Markman, M.¹ Rothman, R.² Hakes, T.³ Reichman, B.⁴ Hoskins, W.⁵ Rubin, S.⁶ Jones, W.⁷ Almadronres, L.⁸ Lewis, J.L.⁹

14
- 0032103330
- Altretamine (hexamethylmelamine) in platinum-resistant and platinum refractory ovarian cancer: A Gynaecologic Oncology Group phase II trial
- (1998) Gynecol Oncol , vol.69 , pp. 226
- Markman, M.¹ Blessing, J.A.² Moore, D.³ Ball, H.⁴ Lentz, S.S.⁵

15
- 0026633113
- Value of CA 125 as a marker of ovarian cancer
- (1992) Eur J Gynaecol Oncol , vol.3 , pp. 360
- Markowska, J.¹ Manys, G.² Kubaszewska, M.³

16
- 0029802958
- Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: A phase III randomised trial in patients with suboptimal stage III/IV ovarian cancer
- (1996) Semin Oncol , vol.23 , pp. 40
- McGuire, W.P.¹ Hoskins, W.J.² Brady, M.F.³ Kucera, P.R.⁴ Partridge, E.E.⁵ Look, K.Y.⁶ Clarke-Pearson, D.L.⁷ Davidson, M.⁸

17
- 0031055830
- Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumour activity and toxicity modification by liposomal encapsulation
- (1997) J Clin Oncol , vol.15 , pp. 987
- Muggia, F.M.¹ Hainsworth, D.² Jeffers, S.³ Miller, P.⁴ Groshen, S.⁵ Tan, M.⁶ Roman, L.⁷ Uziely, B.⁸ Muderspach, L.⁹ Garcia, A.¹⁰ Burnett, A.¹¹ Greco, F.A.¹² Morrow, C.P.¹³ Paradiso, L.J.¹⁴ Liang, L.J.¹⁵

18
- 0033986363
- Phase III randomised study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group (GOG) study
- (2000) J Clin Oncol , vol.18 , pp. 106
- Muggia, F.M.¹ Braly, P.S.² Brady, M.F.³ Sutton, G.⁴ Niemann, T.H.⁵ Lentz, S.L.⁶ Alvarez, R.D.⁷ Kucera, P.R.⁸ Small, J.M.⁹

19
- 0030868378
- Future directions in the chemotherapy of ovarian cancer
- (1997) Semin Oncol , vol.24 , pp. S15-S86
- Ozols, R.F.¹

20
- 0025797321
- Ovarian cancer. Chemotherapy of ovarian cancer
- (1991) Semin Oncol , vol.18 , pp. 222-232
- Ozols, R.F.¹ Young, R.C.²

21
- 0028977865
- Australasian multicentre study of paclitaxel (Taxol) in relapsed ovarian cancer
- (1995) Aust N Z J Med , vol.25 , pp. 337
- Phillips, K.A.¹ Friedlander, M.² Olver, I.³ Evans, B.⁴ Smith, J.⁵ Fitzharris, B.⁶ McCrystal, M.⁷ Joughin, J.⁸ Bishop, J.⁹

22
- 0033041842
- On pushing the outer edge of the outer edge of paclitaxel's dosing envelope
- (1999) Clin Cancer Res , vol.5 , pp. 481
- Rowinsky, E.K.¹

23
- 0032962414
- Use of tumour markers in monitoring the course of ovarian cancer
- (1999) Ann Oncol , vol.10 , pp. S21
- Rustin, G.J.S.¹ Nelstrop, A.E.² Bentzen, S.M.³ Piccart, M.J.⁴ Bertelsen, K.⁵

24
- 0031795302
- First-line chemotherapy for advanced ovarian cancer: Paclitaxel, cisplatin and the evidence
- (1998) Br J Cancer , vol.78 , pp. 1471-1478
- Sandercock, J.¹ Parmar, M.K.² Torri, V.³

25
- 0000264166
- Updated analysis shows highly significant improved overall survival (OS) for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: Mature results of the EORTC-GCCG, NO-COVA, NCIC CTG and Scottish intergroup trial
- (1998) Proc Am Soc Clin Oncol , vol.17 , pp. 1394
- Stuart, G.¹ Bertelsen, K.² Mangioni, C.³ Trope, C.⁴ James, K.⁵ Cassidy, J.⁶ Kaye, S.⁷ Timmers, P.⁸ Roy, J.A.⁹ Piccart, M.J.¹⁰

26
- 0030900145
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
- (1997) J Clin Oncol , vol.15 , pp. 2183
- Ten Bokkel Huinink, W.¹ Gore, M.² Carmichael, J.³ Gordon, A.⁴ Malfetano, J.⁵ Hudson, I.⁶ Broom, C.⁷ Scarabelli, C.⁸ Davidson, N.⁹ Spanczynski, M.¹⁰ Bolis, G.¹¹ Malmstrom, H.¹² Coleman, R.¹³ Fields, S.C.¹⁴ Heron, J.F.¹⁵

27
- 0027395983
- Second-line chemotheraphy for recurrent carcinoma of the ovary
- (1993) Cancer , vol.71 , pp. 1559
- Thigpen, J.T.¹ Vance, R.B.² Khansur, T.³

28
- 0026742779
- Hypersensitivity reactions
- (1992) Semin Oncol , vol.19 , pp. 458
- Weiss, R.B.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.